**MEDICATION PRIOR AUTHORIZATION REQUEST FORM**
**FAX this completed form to 1-888-865-6531**

OR Mail request to: Envolve Pharmacy Solutions PA Dept. | 5 River Park Place East, Suite 210 | Fresno, CA 93720
Call 1-833-705-1351 to request a 72-hour supply of medication.
Envolve Pharmacy Solutions will respond via fax or phone within 24 hours of receipt of all necessary information, except during weekends and holidays. For immediate response on weekends and holidays, NurseWise will answer your call.

Children's Medical Services Health Plan
OPERATED BY SUNSHINE HEALTH

# COLONY STIMULATING FACTORS

**Clinical PA required (preferred): Leukine®/Neupogen® / Nyvepria™**
**Non-preferred: Fulphia™/ Granix®/Neulasta®/Nivestym®/ Udenyca®/ Zarxio®/Ziextenzo™**
**Note: Form must be completed in full. An incomplete form may be returned.**

envolve Pharmacy Solutions

**Recipient's Medicaid ID #**

**Date of Birth (MM/DD/YYYY)** / /

**Recipient's Full Name**

**Prescriber's Full Name**

**Prescriber NPI**

**Prescriber Phone Number** - -

**Prescriber Fax Number** - -

**Pharmacy Name**

**Pharmacy Medicaid Provider #**

**Pharmacy Phone Number** - -

**Pharmacy Fax Number** - -

**Drug Strength/NDC (if available) submitted on claim:** _____

1. What is the diagnosis or the indication for the product? Please check below **AND** submit supporting documentation indicating the diagnosis.
   - ☐ Cancer patient receiving myelosuppressive chemotherapy
   - ☐ Cancer patient receiving bone marrow transplant
   - ☐ Patient receiving induction or consolidated chemotherapy for acute myeloid leukemia (AML)
   - ☐ Peripheral blood progenitor cell collection and therapy in cancer patient
   - ☐ Acute exposure to myelosuppressive doses of radiation in patient
   - ☐ Severe neutropenia in acquired immunodeficiency syndrome (AIDS) patient on antiretroviral therapy
   - ☐ Severe chronic neutropenia in patient (select from the following): ☐ Congenital ☐ Cyclic ☐ Idiopathic

**MEDICATION PRIOR AUTHORIZATION REQUEST FORM**
**FAX this completed form to 1-888-865-6531**

OR Mail request to: Envolve Pharmacy Solutions PA Dept. | 5 River Park Place East, Suite 210 | Fresno, CA 93720
Call 1-833-705-1351 to request a 72-hour supply of medication.
Envolve Pharmacy Solutions will respond via fax or phone within 24 hours of receipt of all necessary information, except during weekends and holidays. For immediate response on weekends and holidays, NurseWise will answer your call.

Children's Medical Services Health Plan
OPERATED BY SUNSHINE HEALTH

# COLONY STIMULATING FACTORS

**Clinical PA required (preferred): Leukine®/Neupogen® / Nyvepria™**
**Non-preferred: Fulphia™/ Granix®/Neulasta®/Nivestym®/ Udenyca®/ Zarxio®/Ziextenzo™**
**Note: Form must be completed in full. An incomplete form may be returned.**

envolve Pharmacy Solutions

**Recipient's Full Name**

| | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

2. This is: ☐ New therapy **OR** ☐ Continuation of therapy
3. Can the prescriber attest the disease state or prescribed regimen is high risk (> 20%) for febrile neutropenia? ☐ Yes ☐ No
4. Lab test date: _____
   Absolute neutrophil count (ANC): _____ cells/$mm^3$
5. What is the date range of therapy? Begin date: _____ End date: _____
6. What will be the dosage and frequency of dosing? _____

Prescriber's Signature: _____ Date: _____

**REQUIRED FOR REVIEW: Copies of medical records (i.e., diagnostic evaluations and recent chart notes) and the most recent copies of related labs. The provider must retain copies of all documentation for five years.**

**MEDICATION PRIOR AUTHORIZATION REQUEST FORM**
**FAX this completed form to 1-888-865-6531**

OR Mail request to: Envolve Pharmacy Solutions PA Dept. | 5 River Park Place East, Suite 210 | Fresno, CA 93720
Call 1-833-705-1351 to request a 72-hour supply of medication.
Envolve Pharmacy Solutions will respond via fax or phone within 24 hours of receipt of all necessary information, except during weekends and holidays. For immediate response on weekends and holidays, NurseWise will answer your call.

Children's Medical Services Health Plan
OPERATED BY SUNSHINE HEALTH

# COLONY STIMULATING FACTORS

**Clinical PA required (preferred): Leukine®/Neupogen® / Nyvepria™**
**Non-preferred: Fulphia™/ Granix®/Neulasta®/Nivestym®/ Udenyca®/ Zarxio®/Ziextenzo™**
**Note: Form must be completed in full. An incomplete form may be returned.**

envolve Pharmacy Solutions

## Approved Indications for Neupogen®, Zarxio®, and Nivestym®

- Cancer patients (Note that they do not have to meet ANC criteria. If they have the indication, approve.):
  - If patient has not yet undergone chemotherapy but it has been prescribed, no ANC is required.
  - Cancer patients receiving myelosuppressive chemotherapy (approve up to 12 months).
  - Cancer patients receiving bone marrow transplants (approve up to 12 months).
  - Patient receiving induction or consolidated chemotherapy for AML (approve up to 12 months).
  - Peripheral blood progenitor cell collection and therapy in cancer patients (approve up to 12 months).
- Severe chronic neutropenia – ANC now required
  - All lab documentation must be on official lab letterhead – handwritten labs are not acceptable.
  - The ANC is 1500 or less.
  - Congenital, cyclic, or idiopathic (approve up to 12 months)
- AIDS – ANC required
  - Severe neutropenia in AIDS patients on antiretroviral therapy
  - Initial Therapy: ANC is 1000 or less.
  - Continuation of Therapy: ANC is 1600 or less.
  - All lab documentation must be on official lab letterhead – handwritten labs are not acceptable. (Approve for 6 months).
- Patients acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome) (Neupogen® only)
  - Approve for one month.

## Approved Indications for Udenyca®, Neulasta®, Ziextenzo™, Nyvepria™, and Fulphila™

- Chemotherapy-induced neutropenia
  - Cancer patient with non-myeloid malignancies receiving myelosuppressive chemotherapy (approve up to 12 months).
- Dosage
  - 6 mg subcutaneous once per chemotherapy cycle
- Patient acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome) (Neulasta® only)
- Dosage
  - Two doses, 6 mg subcutaneous, each one week apart

**Note:**

- Do not administer in the period 14 days before and 24 hours after administration of cytotoxic chemotherapy.
- Documentation of the ANC and/or lab values is not required.
- Not indicated for severe chronic neutropenia.
- Not indicated for neutropenia associated with human immunodeficiency virus (HIV)/AIDS.

**MEDICATION PRIOR AUTHORIZATION REQUEST FORM**
**FAX this completed form to 1-888-865-6531**

OR Mail request to: Envolve Pharmacy Solutions PA Dept. | 5 River Park Place East, Suite 210 | Fresno, CA 93720
Call 1-833-705-1351 to request a 72-hour supply of medication.
Envolve Pharmacy Solutions will respond via fax or phone within 24 hours of receipt of all necessary information, expect during weekends and holidays. For immediate response on weekends and holidays, NurseWise will answer your call.

Children's Medical Services Health Plan
OPERATED BY SUNSHINE HEALTH

# COLONY STIMULATING FACTORS

**Clinical PA required (preferred): Leukine®/Neupogen® / Nyvepria™**
**Non-preferred: Fulphia™/ Granix®/Neulasta®/Nivestym®/ Udenyca®/ Zarxio®/Ziextenzo™**
**Note: Form must be completed in full. An incomplete form may be returned.**

envolve Pharmacy Solutions

**Approved Indications for Granix®**

- Chemotherapy-induced neutropenia:
  - Cancer patient with non-myeloid malignancies receiving myelosuppressive chemotherapy (approve up to 12 months)
- Dosage
  - 5 mcg/kg/day subcutaneously

**Note:**

- Do not administer in the period 24 hours before and 24 hours after administration of cytotoxic chemotherapy.
- Documentation of the ANC and/or lab values is not required.
- Not indicated for severe chronic neutropenia.
- Not indicated for neutropenia associated with HIV/AIDS.

**Approved Indications for Leukine®**

- Use following induction chemotherapy in patients > 55 years with AML: (approve up to 12 months)
  - Safety and efficacy has not been assessed in patients with AML under 55 years of age.
- Bone marrow transplantation: (Approve for 6 months)
  - Mobilization of peripheral blood progenitor cells prior to transplant.
  - Use after myeloablative therapy and transplantation of peripheral blood progenitor cells to improve time to engraftment.
  - Use after autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL), or Hodgkin's disease (HD).
  - Use after allogeneic bone marrow transplantation to accelerate myeloid recovery.
  - Use after allogeneic or autologous bone marrow transplantation in which engraftment is delayed or has failed.